| Abstrakt: |
A recent study conducted at Queen Elizabeth Hospital in Hong Kong evaluated the effectiveness of dual-tracer PET/CT in the management of hepatocellular carcinoma (HCC), a type of liver cancer. The study found that dual-tracer PET/CT provided added value beyond conventional imaging by improving staging, confirming HCC diagnosis with high accuracy in patients with indeterminate lesions, and detecting HCC in patients with unexplained elevation of serum AFP. The use of dual-tracer PET/CT led to upstaging in 12% of patients with HCC undergoing staging, resulting in treatment modification in 8% of cases and a cost saving of $495 per patient. The research suggests that dual-tracer PET/CT can be a valuable tool in the management of HCC. [Extracted from the article] |
